Trifluoroacetic acid → 1-(4-Amino-quinazolin-7-ylmethyl)-4-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-piperazin-2-one
Reaction equation
C(OC([N:8]1[C:16]2[CH:15]=[CH:14][N:13]=[CH:12][C:11]=2[CH:10]=[C:9]1[CH2:17][N:18]1[CH2:23][CH2:22][N:21]([CH2:24][C:25]2[CH:34]=[C:33]3[C:28]([C:29]([NH2:35])=[N:30][CH:31]=[N:32]3)=[CH:27][CH:26]=2)[C:20](=[O:36])[CH2:19]1)=O)(C)(C)C.C(O)(C(F)(F)F)=O>C(Cl)Cl>[NH2:35][C:29]1[C:28]2[C:33](=[CH:34][C:25]([CH2:24][N:21]3[CH2:22][CH2:23][N:18]([CH2:17][C:9]4[NH:8][C:16]5[CH:15]=[CH:14][N:13]=[CH:12][C:11]=5[CH:10]=4)[CH2:19][C:20]3=[O:36])=[CH:26][CH:27]=2)[N:32]=[CH:31][N:30]=1Participants
Reactant 2
Product 1
Reagents, catalysts & solvents 1
Procedure
To a solution containing 2-[4-(4-amino-quinazolin-7-ylmethyl)-3-oxo-piperazin-1-ylmethyl]-pyrrolo[3,2-c]pyridine-1-carboxylic acid tert-butyl ester (50 mg, 0.12 mmol) in CH2Cl2 (5 mL is added TFA (1 mL) at ambient temperature. After 16 h, the reaction mixture is concentrated to dryness, diluted with water and purified by reverse-phase HPLC [Buffer A: water w/0.1% TFA; Buffer B: CH3CN w/0.1% TFA; Gradient: 0% B to 45% B over 30 min] to provide 34 mg (73%, two steps) of the title compound as a white, lyophilized solid. 1H NMR (300 MHz, CDCl3) δ2.77 (s, 3H), 3.23 (s, 2H), 3.31 (m, 2H), 3.89 (s, 2H), 4.00 (br s, 3H), 4.71 (s, 2H), 6.94 (s, 1H), 7.60 (m, 2H), 7.84 (d, J=6.5 Hz, 1H), 8.36 (m, 2H), 8.81 (s, 1H), 9.18 (s, 1H), 9.73 (br s, 2H), 12.87 (s, 1H) ppm; MS (ion spray): m/z 388 (M+H).
Workup
- concentrationthe reaction mixture is concentrated to dryness
- additiondiluted with water
- custompurified by reverse-phase HPLC [Buffer A: water
Sources & evidence
- ORD record
- ord-4933038d5c6e479593b446bb73b624e5
- Source dataset
- uspto-grants-2009_11
- Patent number
- US07612075B2
Reaction notes
Loading…